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Purpose: To evaluate the efficacy of amniotic membrane in corneal
ulcers refractive to conventional treatment and amniotic membrane
with fibrin glue in corneal perforations.
Methods: Amniotic membrane transplantation (AMT) was per-
formed in 33 eyes from 32 patients for corneal ulcers refractive to
conventional treatment. Fourteen ulcers were perforated and received
fibrin glue and amniotic membrane. Ulcers were divided into 3
groups: neurotrophic or exposure, autoimmune, and other etiology.
Results: Overall success was observed in 80% (27/33 eyes) of the
cases, with success rates of 87.5% (14/16 eyes), 70% (7/10 eyes),
85.7% (6/7 eyes) in groups 1, 2, and 3, respectively. The ulcers healed
in a mean time of 3.66 1.6 weeks and the follow-up was 14.8 6 9.9
months. Failure was noted in 6 eyes with severe neurotrophic
keratitis, Stevens-Johnson syndrome, ocular cicatricial pemphigoid,
and Acanthamoeba keratitis. Grafts with fibrin sealant showed a
success rate of 92.9 % (13/14 eyes) compared to 73.7% (14/19 eyes)
for amniotic grafts alone. In patients with severe limbal damage, a
success rate of only 20% (1/5) was observed.
Conclusions: AMT is a viable option in the treatment of nonhealing
corneal ulcers of various depth and etiologies. Perforations up to 3 mm
can be safely managed by fibrin glue and AMT. These techniques
lead to rapid reconstruction of the corneal surface and can give a good
final functional result or allow keratoplasty to be done in more favor-
able conditions.
Key Words: amniotic membrane, corneal ulcer, corneal perforation,
fibrin glue
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Corneal epithelial defects usually heal without complica-tions. However, many factors can interfere with wound
healing, including dry eye, lid malfunction, inflammation, in-
fection, or damage to corneal nerves. These factors are found
in primary ocular surface disorders, such as neurotrophic
keratitis and keratoconjunctivitis sicca, or in systemic diseases,
such as rheumatoid arthritis, ocular cicatricial pemphigoid, and
Stevens-Johnson syndrome. When corneal stem cells, epithe-
lial cells, and epithelial basement membrane are damaged by
persistent inflammation, epithelial defects, corneal scarring
and neovascularization may develop.1 Moreover, matrix
metalloproteinases produced by keratocytes,2 epithelial cells,
and neutrophils3 can cause progressive stromal ulceration,
which can lead to corneal perforation.
Current treatments include artificial tears, lubricants,
patching, therapeutic bandage contact lenses,4 and scleral
lenses.5 Experimental trials with fibronectin,6 insulin growth
factor, substance P,7 and nerve growth factor8 have also been
attempted, with limited success. If the defect progresses,
surgical treatments such as tissue adhesives,9 tarsorrhaphy,
conjunctival flaps,10 and penetrating or lamellar keratoplasty11
if corneal perforation ensues may become necessary. However,
these surgical modalities are associated with a large number of
problems including tissue inflammation from glue toxicity,
diminished vision, and poor cosmesis with a conjunctival flap
and tarsorrhaphy and graft failure in the setting of an inflamed
or infected eye.11
In 1997, Lee and Tseng12 were the first to propose the use
of human amniotic membrane (AM) for the treatment of corneal
epithelial defects. Subsequently, AM transplantation (AMT)
was applied to patients with cicatricial eye diseases,13 pte-
rygium,14 and ocular surface reconstruction after removal of
large conjunctival lesions15 or following chemical or thermal
burns.16 AMT has been shown to promote epithelial healing and
to reduce vascularization, inflammation, and scarring. Kruse
et al17 showed rapid epithelial healing and stromal thickening
after multilayer AMT in patients with deep corneal ulcers. In
2000, Chen et al18 reported AMT as an effective alternative for
treating severe neurotrophic ulcers, and recently they described
the favorable outcome of 34 eyes with AMT for corneal ulcers
and perforations of less than 0.5 mm in diameter.19
This study evaluates the efficacy of AM in the man-
agement of a variety of corneal ulcers, central and paracentral,
and reports the outcome of perforations up to 3 mm in dia-
meter treated by fibrin glue and AMT.
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PATIENTS AND METHODS
We studied 33 cases of AMT (32 patients) for corneal
ulcers performed between 1997 and 2002. They were managed
at 3 different sites (Centre Hospitalier Universitaire de Liège,
Belgium [n = 20] and Centre Hospitalier Universitaire de
Montréal and Maisonneuve-Rosemont Hospital, Canada [n =
13]). This retrospective review conformed to the requirements
of the ethics committee of each of the 3 centers. Criteria for
inclusion were refractory corneal ulcers, including corneal
ulcers with perforations smaller than 3 mm in diameter.
Patients were referred by different ophthalmologists after
failure of conventional treatment of the ulcer for a minimum of
4 weeks. In all cases, toxic topical medications were removed
and lubrication, punctal occlusion if appropriate, and bandage
contact lenses were tried without success. Clinical data
including patient demography, etiology, surgical procedure,
associated therapies, visual acuity, complications, and final
outcome were retrieved retrospectively. Patients were divided
in 3 groups according to etiology of corneal disease: group 1
for neurotrophic keratitis, group 2 for autoimmune diseases,
and group 3 for others. Patients with corneal ulcer received
AMT alone, and patients with corneal perforations were
managed by fibrin glue and AMT. Surgical success was de-
fined as cessation of aqueous leakage and formation of a
deep anterior chamber in cases with perforation, complete
epithelialization of ocular surface, and the presence of a visible
stromal thickness at the operated site by the second month
following AMT. Failure was defined as persistence or re-
currence of aqueous leakage, lack of or incomplete epithe-
lialization, or recurrence of corneal ulceration at the same
site at 2 months.
Preparation of Preserved AM
Human AM was prepared and preserved using a method
previously described by Lee and Tseng.12 AMs for Montreal
were obtained from Bio-Institute (Miami, FL) and AMs for
Liège were acquired and preserved at the eye bank of Liège
(Belgium) following the same protocol. Human immunode-
ficiency virus, human hepatitis types B and C, and syphilis had
been excluded by serologic tests.
Amniotic Membrane Transplantation
Procedures were performed by 3 surgeons (P.E.D, B.D.,
and M.M.) using topical (n = 16), peribulbar (n = 8), or general
(n = 9) anesthesia. The base of the ulcer was debrided with
fine forceps and a microsponge, and the poorly adherent
epithelium adjacent to the edge of the ulcer was removed. One
or 2 pieces of AM were removed from the nitrocellulose paper
filter and transferred onto the ulcer with the basement
membrane facing up. Interrupted sutures or a running 10-0
nylon suture secured the AM beyond the edge of the defect.
For patients 16 and 24, 3 and 4 pieces of AM, respectively,
were used. In these cases, small pieces were stacked one above
the other to fill the cavity of the ulcer, and a larger piece was
used to cover the ulcer and the deepithelialized zone. This
membrane was then secured with interrupted sutures.
Corneal perforations were managed using a fibrin glue
(Tissucol, Baxter, Belgium or Tisseel, Baxter, Deerfield, IL)
and AMT. A small volume of sodium hyaluronate viscoelastic
(Healon, Pharmacia, Brussels, Belgium or Pharmacia,
Montreal, Canada) was used to restore an adequate anterior
chamber depth. Debridement and epithelium removal were
performed with a blunt blade. After cleaning and drying of the
ulcer, the fibrin glue was used to fill up the perforation site
creating a fibrin plug. An AM (basement membrane side up)
was then used to cover and secure the fibrin plug using
interrupted sutures.
A bandage contact lens was applied in all cases until the
epithelial defect completely healed. Patients received a com-
bination of corticosteroid-antibiotic drops 3 to 4 times daily.
They were examined on postoperative day 1, then weekly until
complete epithelialization occurred, monthly for 3 months,
and every 3 to 6 months thereafter.
Statistical Analysis
The qualitative data were analyzed by x2 exact test and
the quantitative postoperative data were analyzed by t tests and
ANOVA (SAS version 8.2). A P value of less than 0.05 was
considered to be statistically significant.
RESULTS
Thirty-two patients were involved, 16 men and
16 women (Table 1). The average age of our population
was 62 6 17.8 years (range, 16–85). The average follow-up
was 14.86 9.9 months (range, 1–36). Patients were divided in
3 groups according to the ulcers’ etiology. Group 1 (16 eyes)
included neurotrophic and exposure ulcers. Group 2 (10 eyes)
included ulcers associated with autoimmune diseases such as
Stevens-Johnson syndrome (n = 2), Sjögren syndrome (n = 3),
ocular cicatricial pemphigoid (n = 1), rheumatoid polyarthritis
(n = 3), and Lyell disease (n = 1). Group 3 (7 eyes) was
composed of ulcers of different etiologies.
When considering all ulcers, perforated or not, 30 of 33
eyes (90%) epithelialized within 3.6 6 1.6 weeks (Table 2).
The ulcer reoccurred within 2 months in 4 eyes (13%), with
a mean recurrence time of 6.5 6 1.9 weeks. The AMT was
successful in ulcer reconstruction in 27 of 33 eyes (81%), after
1 (26 patients) or 2 (1 patient) procedures. Patient 32 was
counted as a success but died 1 month later. In patients with
successful AMT, the anterior chamber was deep, and there was
no further leakage of aqueous fluid; the site of the ulcer
showed a subepithelial scar with, in some cases, a thickening
of the stroma, and epithelialization was complete. Conjunc-
tival inflammation and pain were reduced in all patients,
although pain relief was not specifically quantified. The final
visual acuity remained unchanged in 11 eyes, improved in 17
eyes, and decreased in 2 eyes. Of the 17 patients with
improved visual acuity, 8 gained 2 lines or more on the Snellen
chart. In 2 patients, the preoperative visual acuity was not
recorded. In general, the final acuity remained weak with 20
eyes (60%) seeing 20/200 or less.
Among the 3 groups, the success rate, ie, epithelial
healing with stable corneal surface within the first 2 post-
operative months, was 87.5% in group 1, 70% in group 2, and
86 % in group 3. The mean epithelialization times after AMT
and the mean follow-up for each group are summarized in
370 q 2005 Lippincott Williams & Wilkins
Hick et al Cornea  Volume 24, Number 4, May 2005
TABLE 1. Clinical Data and Surgical Outcome







1/55/M OD Ulcer Neurotrophic, post-HSK
Diffuse limbal deficiency
AMT No 1
2/74/M OD Ulcer Neurotrophic AMT No 1
3/76/F OD Ulcer Neurotrophic, post-infectious
(streptococcal)
AMT No No
4/16/F OD Ulcer Neurotrophic AMT No 5
Damage to V1 2nd AMT 5




6/52/M OS Ulcer Exposure Keratitis Lid surgery AMT No 1
7/77/M OD Ulcer +
perforation
1 mm
Neurotrophic Diabetic mellitus AMT +
fibrin glue
No 6
8/69/F OD Ulcer Exposure Keratitis Lid surgery AMT No 4
9/66/F OS Ulcer Neurotrophic + exposure
Damage to V et VII
Meningioma removal
AMT SK 2
10/81/F OD Ulcer Neurotrophic Failed
graft HZV
AMT No 3.5
11/28/F OS Ulcer Neurotrophic HSV AMT No 2






















15/43/M OS Ulcer Neurotrophic Post-infectious AMT No 6
16/56/M OS Ulcer Neurotrophic AMT No 2
HSV 2nd AMT ML No 1
Autoimmune diseases
17/36/M OD Ulcer Stevens-Johnson Diffuse
limbal deficiency
AMT No No
18/68/F OD Ulcer +
perforation
2 mm
Sjögren syndrome AMT +
Fibrin glue
Prednisone 6
19/68/F OS Ulcer +
perforation
2 mm
Sjögren syndrome AMT +
Fibrin glue
Prednisone 6
20/80/M OD Ulcer +
perforation
1.5 mm
Ocular Pemphigoid AMT +
Fibrin glue
Immuran 3
Diffuse limbal deficiency 2nd AMT +
Fibrin glue
4
21/81/F OS Descemetocele +
perforation
0.5 mm





22/72/M OS Ulcer +
perforation
2 mm








23/85/F OS Ulcer +
perforation
2 mm




Prednisone 2 Fibrin glue
(continued on next page)
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TABLE 1. (continued) Clinical Data and Surgical Outcome






24/82/F OD Ulcer +
perforation
3 mm
RA Corneal graft AMT ML +
Fibrin glue
Méthotrexate 3







26/50/F OS Ulcer Stevens-Johnson syndrome AMT No No
Diffuse limbal deficiency
Other etiology
27/59/F OS Ulcer Acantamoeba keratitis AMT No 7
28/34/M OD Ulcer Staph aureus keratitis
Congenital glaucoma
AMT No 4
29/68/F Ulcer PBK AMT No 6
30/44/F OS Ulcer + perforation 1 mm Permanent CL Coma AMT +
Fibrin glue
No 4





32/52/M OD Ulcer PBK Ca++ keratopathy
Tropical anesthetics
AMT SK EDTA 3














2/74/M No LP LP S 2
3/76/F NA LP- LP- F Recurrence at 1 month
Conjunctival flap
19
4/16/F 54 20/100 20/100 S 18
No
5/82/M No 20/100 20/80 S 2
6/52/M 14 20/400 20/300 S Recurrence at 3 months
Tarsorraphy
12
7/77/M No 20/200 20/80 S 10
8/69/F No 20/100 20/25 S 6
9/66/F No HM FC 50 cm S 24
10/81/F No HM HM S Vascularized cornea 18
11/28/F No 20/100 20/30 S 4
12/74/F No LP LP S 24
13/74/M No HM HM S 21
14/78/M No FC 20/200 S 21
15/43/M No 20/100 20/60 S 2
16/56/M 4 LP LP S 5
No
Autoimmune diseases




18/68/F No NR 20/100 S 13
19/68/F No NR 20/60 S 13
20/80/M 8 FC 30 cm FC 1 m F Perforation recurred
at 2 months
9
7 Repeat AMT + Tisseel
Reperforation after
2 months
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Table 2. No statistically significant differences were found
between the postoperative data of the 3 groups.
Failures included eyes with neurotrophic keratitis (n =
2), autoimmune disorders (n = 3), and persistent amoebic
keratitis (n = 1).
Two patients received a second AMT during the 2 first
months of follow-up. Repeat AMT allowed for a stable
epithelium for one of them (patient 16), and this case was
considered as a success. The other one suffered from ocular
cicatricial pemphigoid (case 20) and was not successful in
achieving a stable epithelium after repeat AMT.
Table 3 comprises the results according to the technique
used: AMT alone or AMTwith fibrin glue. Success rates were
74% and 93% for each group, respectively. Differences
between the 2 groups were not statistically significant.
Table 4 compares the results according to limbal
involvement. Patients with limbal deficiency showed a 20%
success rate, whereas in patients with a normal limbus, it
reached 93%. This difference was statistically significant
(P = 0.0017).
CASE REPORTS
Ulcer From Exposure Keratitis: Case 8
A 69-year-old patient had undergone several lid surgeries for
ptosis in the right eye. Over the last 2 years preceding his visit to our
department, he had developed a large corneal ulceration resisting
medical treatment (Fig. 1). The eye was sore, and the visual acuity
was 20/100. An AMT was performed. After excision of necrotic
material from the base of the ulcer, a conjunctival peritomy was
performed inferiorly. The AMwas placed on the ulcer overlapping the
limbus and sutured with 10-0 nylon. The following day, the pain had
disappeared, and 27 days later, the ulcer had reepithelialized. At the
6-month postoperative visit, a nonvascularized inferior nebula was
noted while visual acuity had improved to 20/25. The scar remained
stable after a 1-year follow-up.
TABLE 1. (continued) Clinical Data and Surgical Outcome
Case/Age/Sex
Recurrence of
ED (weeks) Pre-op VA Post-op VA Result Evolution
F/up
(months)
21/81/F No FC 2 m 20/100 S 6
22/72/M No 20/200 20/40 S 25
23/85/F No FC 30 cm 20/40 S 22
24/82/F No HM FC 1 m S 18
25/48/M No HM FC 30 cm S 13







27/59/F 8 HM HM F Recurrence at 2 months
Keratoplasty
36
28/34/M No LP- LP- S 36
29/68/F No 6/120 HM S 10
30/44/F No 20/400 20/60 S 10
31/52/M No NR 20/20 S 6
32/52/M No LP LP S Died 1 month after
surgery
1
33/78/M No 20/200 20/200 S 20
AMT, amniotic membrane transplantation; HSK, Herpes simplex keratitis; CF, counting fingers; F, failure; S, success; NA, not applicable; NR, not recorded; PED, persistent
epithelial defect; ED, epithelial defect; SK, superficial keratectomy; ML, multilayer; LP, light perception; CL, contact lens; PBK, pseudophakic bullous keratitis; RA, rheumatoid arthritis;
DCR, dacryocystorhinostomy.
TABLE 2. Results in Group 1,2,3 and the 3 Groups Combined
Group 1 (n = 16) Group 2 (n = 10) Group 3 (n = 7) P Value Combined (n = 33)
Complete Epithelialization (No, %) 15 (93.7%) 8 (80%) 7 (100%) 0.4208 (x2 exact test) 30 (90.9%)
Epithelialization time (weeks) 2.9 6 1.8 (1–6) 3.9 6 1.8 (1–7) 4.6 6 1.6 (3–6) 0.1181 (ANOVA) 3.6 6 1.8 (1–7)
Recurrence of ulcer after first AMT (No, %) 4 (26.7%) 1 (12.5%) 1 (14.3%) 0.7211 (x2 exact test) 6 (20%)
Success (No, %) 14 (87.5%) 7 (70%) 6 (85.7%) 0.5171 (x2 exact test) 27 (81.8%)
Follow-up (months) 12.3 6 8.3 (2–24) 17.3 6 8.7 (6–36) 17 6 14.2 (1–36) 0.3787 (ANOVA) 14.8 6 9.9 (1–36)
AMT, amniotic membrane transplantation.
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Perforated Ulcer in a Patient With Rheumatoid
Arthritis: Case 24
An 82-year-old patient suffering from long-standing rheuma-
toid arthritis and poorly compliant to systemic treatment was admitted
for a corneal perforation to the right eye, which had undergone
corneal transplantation several years before (Fig. 2). The patient
presented with a diffuse stromal thinning. The visual acuity was hand
motion. The anterior chamber was shallow. The descemetocele had
a diameter of 4.5 mm and the perforation was 3 mm. After injecting
high viscosity hyaluronic acid in the anterior chamber, the ulcer was
cleaned and the stromal bed was dried. A drop of fibrin glue was
applied. A 3 3 4-mm AM was then placed epithelium side up and
covered by a larger 10 3 14-mm piece was inserted under the
lower conjunctiva and attached with an episcleral suture. A bandage
contact lens was applied. Complete reepithelialization was observed
after 20 days. The scarring remained stable after a follow-up of
18 months.
DISCUSSION
Our study demonstrates the effectiveness of the AMT in
the treatment of refractory corneal ulcers with or without
perforations up to 3 mm in diameter. Eighty-two percent of
patients epithelialized within 3.6 weeks and had a stable
corneal surface at least for 2 months after the surgery. These
results are comparable to those obtained in previous studies
using the AM to treat ulcers and corneal perforation.18,19,22,23
This series, which is one of the largest, is the only one
involving perforations 0.5–3.0 mm in diameter.
The transplantation of an AM presents several advan-
tages. The tissue, which is readily available and fully meets our
needs, can be kept at 280 for many months. The AM does
not express the antigens HLA-A, B, or DR and therefore poses
no problem of immunological rejection.20 AMT may allow
postponement of corneal grafting until the eye is less
inflamed, thereby improving graft survival or even avoiding
it altogether, if the result is sufficiently functional. The
amniotic membrane presents various advantages over con-
junctival flaps. It is absorbed during the weeks and months
following the intervention until it dissolves and is then
replaced by new fibrous tissue,21 which restores a certain
thickness with an imperfect transparency. In vascularized
corneas, the resorption of AM is rapid due to the abundance
of inflammatory cells.21 The AM causes less visual acuity loss
and less corneal vascularization and allows better cosmetic
results than conjunctival flaps.22
Successful epithelialization may be explained by
different mechanisms. AM provides a basement layer pro-
moting the adhesion, migration, and differentiation of ep-
ithelial cells while preventing apoptosis.20 Also, the AM
contains growth factors that may promote the epithelialization
process.24,25 Nerve growth factor (NGF) seems to play an
important role. It appears to promote the expansion of the
progenitor limbal stem cells and appears to be present in large
quantities in AMs.26 Moreover, AMT constitutes a mechanical
protection to the fragile corneal epithelium, allowing sufficient
oxygenation and hydration of the epithelial cells.27
In our series and according to prior studies,17–19,22
we noted a reduction in the level of conjunctival inflammation
and pain after AMT. This is explained by the fact that
the stroma of the AM stimulates apoptosis of inflammatory
cells,28 suppresses cytokines (interleukin-1a and interleukin-
1b, interleukin-2, interleukin-8, interferon gamma, and
tumor necrosis factor a)19 and contains various proteinase
inhibitors29 and antiinflammatory proteins.30 This local
antiinflammatory activity of the AM helps in more rapid
epithelialization. Resolution of epithelial defect in association
with the antiinflammatory properties of AM tends to stop the
progressive destruction of the stroma.27
Fourteen patients presented initially with a perforated
ulcer. Fibrin glue was applied at the perforation site and AM
was grafted subsequently.31 In the Salomon et al19 series in
TABLE 3. Results in Patients With AMT and AMT + Fibrin Glue
AMT (n = 19) AMT + Fibrin Glue (n = 14) P Value
Complete epithelialization (No, %) 16 (84.2%) 14 (100%) 0.2443 (x2 exact test)
Epithelialization time (weeks) 3.5 6 2 (1–7) 3.6 6 1.7 (2–6) 0.8388 (t-test)
Recurrence of ulcer after first AMT (No, %) 6 (35.3%) 1 (7.1%) 0.1755 (x2 exact test)
Success (No, %) 14 (73.7%) 13 (92.9%) 0.2085 (x2 exact test)
Follow-up (months) 14.6 6 12 (1–36) 15 6 6.6 (6–25) 0.9017 (t-test)
AMT, Amniotic membrane transplantation.
TABLE 4. Results in Patients With Limbal Deficiency and With Normal Limbus
Limbal Deficiency (n = 5) Normal Limbus (n = 28) P Value
Complete Epithelialization (No, %) 3 (60%) 27 (96.4%) 0.0532 (x2 exact test)
Epithelialization time (weeks) 2.50 6 1.5 (1–2.5) 3.69 6 1.9 (1–7) 0.3058 (t-test)
Recurrence of ulcer after first AMT (No, %) 2 (66.7%) 4 (14.8%) 0.0936 (x2 exact test)
Success (No, %) 1 (20%) 26 (92.9%) 0.0017 (x2 exact test)
Follow-up (months) 17 6 11 (9–36) 14.4 6 9.8 (1–36) 0.5995 (t-test)
AMT, Amniotic membrane transplantation.
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2002,10 patients presented with a perforated corneal ulcer.
None of these perforations exceeded 0.5 mm in diameter, and
the AMT alone was successful in 8 patients. Prabhasawat
et al22 reported 5 cases of perforation of less than 1 mm, with 4
of them being successfully treated with multilayer AMT. Our
study looks into perforations measuring 1.96 1.7 (range, 0.5–
3.0) mm in diameter. At this stage, the AM by itself cannot fill
the gap. The fibrin glue is used to close the perforation. It is
composed of a solution containing fibrinogen and thrombin
solution that are combined at the level of the perforation site.
The duplojet system, available with the product, consists of
a set of 2 syringes with a common piston that allows the 2
solutions to flow at the same rate into a connection piece prior
to being mixed together in the application cannula and being
ejected. The resulting fibrin plug is then secured with the AM.
Interesting properties are attributed to this fibrin glue: it
FIGURE 1. A, Patient with large in-
ferior ulcer. B, Cleaning of the ulcer
bed (surgical microscopic view). C,
The amniotic membrane is anchored
with interrupted sutures (surgical mi-
croscopic view). D, Complete healing
with stromal scar and no vasculariza-
tion.
FIGURE 2. A, Perforation of 3 mm on
corneal graft. B, Aspect on the first day
after the operation. C and D, At 6
months, dissolution of the amniotic
membrane and stable epithelium.
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stimulates fibroblasts activity, provides a matrix for migration
of keratocytes, and is not toxic. This results in activation of the
wound healing process.30,31
All patients with AMT and fibrin glue epithelialized
successfully and had a stable scar over time, except for patient
26 with severe Stevens-Johnson syndrome and diffuse limbal
deficiency. The success rate (reepithelialization and stable
corneal surface at 2 months) in perforated ulcers treated with
AMT and fibrin glue (92%) was higher than in nonperforated
ulcers treated with AMT only (74%), although this difference
did not reach statistical significance. In our hands, the AMT–
fibrin glue association was shown to be an efficient tool in the
management of ulcers perforated up to 3 mm in diameter.
Failures occurred in 2 patients with neurotrophic
keratitis, in 3 patients with autoimmune diseases and severe
limbal deficiency, and in 1 patient with amoebic keratitis.
These failures underline the limitations of the AM: persistent
inflammation of the ocular surface; diffuse deficiency of the
limbal stem cells, which prevents the regeneration of corneal
epithelial cells; and damage to the sensory innervation of the
cornea, which prevents epithelial regeneration and retention of
epithelial integrity.
Of 5 patients presenting severe limbal deficiency,
clinically diagnosed by the loss of the palisades of Vogt and
encroachment by conjunctival tissue, the AM only revealed to
be efficient in 1 case. The 4 failures (post-HSV neurotrophic
[n = 1], Stevens-Johnson syndrome [n = 2], and ocular
cicatricial pemphigoid [n = 1]) had a diffuse limbal deficiency,
whereas 90 degrees of healthy limbus remained in the last case
(Lyell disease). Limbal stem cells are necessary for normal
corneal epithelial repopulation, preventing conjunctival epi-
thelial invasion, which may result in surface inflammation,
neovascularization, and recurrent erosions. Our study sug-
gests, on the one hand, that preservation of a portion of healthy
limbus is a prerequisite to successful AMT in patients with
widespread inflammatory or neurotrophic disorders, and on
the other that the AMT on its own might be sufficient to treat
corneal ulcers with partial limbal deficiency. In the presence of
360-degrees limbal deficiency, stem cell transplantation be-
comes necessary. These data corroborate those of Lagoutte
et al32 and Anderson et al,33 who suggest that the AMT allows
the restoration of the corneal epithelium surface in patients
presenting partial limbal deficiency, by promoting the regen-
eration and expansion of the remaining stem cells.
In our study, contrary to other reports,19,34 patients with
rheumatoid arthritis were amenable to the AMT treatment.
Rheumatoid arthritis ulcers are known to be difficult to treat.35,36
In these patients, rapid restoration of systemic immunosup-
pression stopped the inflammation and progressive destruction
of the corneal stroma and allowed the AM to fulfill its role.
In conclusion, AMT represents a viable approach for the
treatment of chronic corneal ulcers resistant to conventional
treatment in patients with healthy residual limbal stem cells.
Moreover, this study demonstrates the advantages of the fibrin
glue in association with AMT in the management of corneal
perforations of up to 3 mm in diameter. This technique pro-
motes a stable and rapid reconstruction of the ocular surface.
AM transplantation should be considered as an initial
procedure before keratoplasty or conjunctival flap. It can also
be used as a temporary measure in cases requiring penetrating
keratoplasty at a later time when the eye is less inflamed and
the corneal surface has reepithelialized.
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